2019 Fiscal Year Final Research Report
Exploration of novel prostate cancer predictive markers using patient-derived xenograft models
| Project/Area Number |
17K11132
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
Terada Naoki 宮崎大学, 医学部, 講師 (60636637)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Keywords | 前立腺癌 / マウスモデル / 去勢治療抵抗性 / Il13Ra2 |
|---|
| Outline of Final Research Achievements |
The therapy for castration resistant prostate cancer (CRPC) diversifies while a new therapeutic drug for prostate cancer are present. Development of the biomarker is urgently needed for appropriate therapeutic drug choice. We established Patient derived xenograft(PDX) models for a prostate cancer clinical condition elucidation. The PDX models resembles an original cancer for pathological molecular study. IL13Ra2 which was considered to be a candidate by using PDX was identified as a potential biomarker for predicting castration-resistance of prostate cancer.
|
| Free Research Field |
前立腺癌
|
| Academic Significance and Societal Importance of the Research Achievements |
前立腺癌の治療は多様化している、特に去勢治療抵抗性前立腺癌となった病態は進行性であり、治療に難渋する。去勢治療抵抗性前立腺癌に対する新規治療薬は複数あるが、適切に病態を反映するマーカーが存在しない。このため、治療薬の選択が非常に難しい状態である。
前立腺癌病態解明のために新規に樹立したマウスモデルを使用し、前立腺癌去勢療法反応性予測マーカーの発見は臨床的に非常に大きな意義があると考える。
|
